Issue link: https://www.e-digitaleditions.com/i/1543258
Inhalation February 2026 21 31. Hofmann, W. Modelling inhaled particle deposi- tion in the human lung—A review. Journal of Aero- sol Science 42: 693-724 (2011). 32. Rostami, A. A. Computational modeling of aero- sol deposition in respiratory tract: A review. Inhala- tion Toxicology 21: 262-290 (2009). 33. Koullapis, P., et al. Multiscale in silico lung mod- eling strategies for aerosol inhalation therapy and drug delivery. Current Opinion in Biomedical Engi- neering 11: 130-136 (2019). 34. Duke, D. J. et al. Volatile propellant droplet evaporation measurements in metered dose inhaler sprays. Aerosol Science and Technology 57(12): 1280-1293 (2023). 35. Gregson, F. K. A., et al. Drying kinetics of salt solution droplets: Water evaporation rates and crys- tallization. Journal of Physical Chemistry B 123: 266-276 (2019). 36. Ivey, J. W. et al. A correlation equation for the mass median aerodynamic diameter of the aerosol emitted by solution metered dose inhalers. Interna- tional Journal of Pharmaceutics 465: 18-24 (2014). 37. Eshaghi, S. et al. In silico investigation of inhala- tion condition impacts on hygroscopic growth and deposition of salbutamol sulphate in human air- ways. Respiratory Physiology & Neurobiology 326: 104271 (2024). 38. Wong, W. et al. The use of computational approaches in inhaler development. Advanced Drug Delivery Reviews 64: 312-322 (2012). 39. Parker, J. Barriers to green inhaler prescribing: Ethical issues in environmentally sustainable clini- cal practice. Journal of Medical Ethics 49(2): 92-98 doi:10.1136/jme-2022-108388 (2022). 40. Woodcock, A. et al. e environmental impact of inhaled therapy: Making informed treatment choices. European Respiratory Journal 60: 3016- 3022 (2022). 41. Hoppentocht, M. et al. Technological and prac- tical challenges of dry powder inhalers and formula- tions. Advanced Drug Delivery Reviews 75: 18-31 (2014). 42. Zhou, Q. T. et al. Effect of device design on the aerosolization of a carrier-based dry powder inhal- er—A case study on Aerolizer ® Foradile ® . AAPS Journal 15: 511-522 (2013). 43. de Boer, A. H. et al. Computational fluid dynam- ics (CFD) assisted performance evaluation of the Twincer™ disposable high-dose dry powder inhaler. Journal of Pharmacy and Pharmacology 64: 1316- 1325 (2012). 44. Borghardt, J. M. et al. Pharmacometric mod- els for characterizing the pharmacokinetics of orally inhaled drugs. AAPS Journal 17: 853-870 (2015). therapeutic possibilities and technological challenges. Lancet Respiratory Medicine 1(5):402-413. (2013). 17. Flint, R. et al. Stability considerations for bacte- riophages in liquid formulations designed for nebu- lization. Cells 12(16): 2057. Preprint at https://doi. org/10.3390/cells12162057 (2023). 18. Shi, C. et al. In vitro - in vivo - in silico approach in the development of inhaled drug products: Nanocrystal- based formulations with budesonide as a model drug. Asian Journal of Pharmaceutical Sci- ences 16: 350-362 (2021). 19. Party, P. et al. Formulation and in vitro and in silico characterization of "nano-in-micro" dry powder inhalers containing meloxicam. Pharmaceutics 13: 1-18 (2021). 20. Singh, S. et al. Advances in artificial intelligence (AI)-assisted approaches in drug screening. Artificial Intelligence Chemistry 2: 100039 (2024). 21. Zhou, G. et al. An artificial intelligence accel- erated virtual screening platform for drug discovery. Nature Communications 15: (2024). 22. Zhang, K. et al. Artificial intelligence in drug development. Nature Medicine. 31: 45-59. Preprint at https://doi.org/10.1038/s41591-024-03434-4 (2025). 23. Varol, D. AI in the pharmaceutical industry: Inno- vations and challenges. https://www.scilife.io/blog/ ai-pharma-innovation-challenges. Scilife (2025). 24. Xu, Z. et al. A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: A ran- domized phase 2a trial. Nature Medicine 31: 2602- 2610. doi:10.1038/s41591-025-03743-2 (2025). 25. Belli, B. Developing an inhalable formulation of the first generative AI drug. ONdrugDelivery (November 2023). 26. Niazi, S. K. et al. Artificial intelligence in drug development: Reshaping the therapeutic landscape. erapeutic Advances in Drug Safety. Preprint at https://doi.org/10.1177/20420986251321704 (2025). 27. Chopra, H. et al. Revolutionizing clinical trials: e role of AI in accelerating medical breakthroughs. International Journal of Surgery 109: 4211-4220 (2023). 28. Fröhlich, E. et al. Development of co-amorphous systems for inhalation therapy—Part 1: From model prediction to clinical success. Pharmaceutics 17(7): 922 (2025). 29. Ros, H. et al. Efficient discovery of new med- icine formulations using a semi-self-driven robotic formulator. ChemRxiv. Preprint at https://doi. org/10.26434/chemrxiv-2024-mwlg6 (2024). 30. Fu, C. et al. e future of pharmaceuticals: Arti- ficial intelligence in drug discovery and development. Journal of Pharmaceutical Analysis a 15: 101248 (2025).